Incruse Ellipta and Insulin glargine and lixisenatide
Determining the interaction of Incruse Ellipta and Insulin glargine and lixisenatide and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: umeclidinium
Brand name: Incruse Ellipta
Synonyms: n.a.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin Glargine and Lixisenatide
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Incruse Ellipta-Insulin glargine and lixisenatide Subcutaneous
- Incruse Ellipta-Insulin glargine, recombinant Subcutaneous
- Incruse Ellipta-Insulin glulisine
- Incruse Ellipta-Insulin Glulisine (Cartridges and Pens)
- Incruse Ellipta-Insulin Glulisine (Vials)
- Incruse Ellipta-Insulin glulisine Subcutaneous
- Insulin glargine and lixisenatide-Indacaterol
- Insulin glargine and lixisenatide-Indacaterol and Glycopyrrolate
- Insulin glargine and lixisenatide-Indacaterol and glycopyrrolate Inhalation
- Insulin glargine and lixisenatide-Indacaterol inhalation
- Insulin glargine and lixisenatide-Indacaterol Maleate
- Insulin glargine and lixisenatide-Indapamide